Get the Stockscreener App
29.48
2.15%
0.62
Arcus Biosciences Inc stock is traded at $29.48, with a volume of 1.15M.
It is up +2.15% in the last 24 hours and up +4.06% over the past month.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
See More
Previous Close:
$28.86
Open:
$28.55
24h Volume:
1.15M
Relative Volume:
0.94
Market Cap:
$3.75B
Revenue:
$236.00M
Net Income/Loss:
$-369.00M
P/E Ratio:
-9.2623
EPS:
-3.1828
Net Cash Flow:
$-489.00M
1W Performance:
+3.00%
1M Performance:
+4.06%
6M Performance:
+55.81%
1Y Performance:
+197.48%
1-Day Range:
$27.97
$29.68
1-Week Range:
$27.95
$29.68
52-Week Range:
$9.81
$31.73
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
29.48 | 3.69B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-13-26 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside - TradingView
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - finance.yahoo.com
(RCUS) Volatility Zones as Tactical Triggers - Stock Traders Daily
A New Arcus Employee Receives Options With a $28.72 Exercise Price - Stock Titan
Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating - Yahoo Finance
HC Wainwright Issues Optimistic Forecast for RCUS Earnings - MarketBeat
Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $42 - Moomoo
Arcus Biosciences Q2 Earnings Call Highlights - MarketBeat
Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism - Yahoo Finance
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $42 to $45 - Moomoo
Arcus Biosciences (NYSE: RCUS) gets 24.7% ownership from Gilead - Stock Titan
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), NewAmsterdam Pharma Company (NAMS) and Revolution Medicines (RVMD) - The Globe and Mail
Arcus Biosciences Inc (RCUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Arcus Biosciences (RCUS) Stock Can Casdatifan Carry Mounting Losses - Sahm
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS) - The Globe and Mail
RCUS Maintained by Wells Fargo -- Price Target Raised to $26.00 - GuruFocus
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $26.00 - MarketBeat
RCUS Maintained by Wedbush -- Price Target Raised to $43.00 - GuruFocus
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.25, Implies 38% Upside - TradingView
Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating - Yahoo Finance
Arcus Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Arcus Biosciences Inc (RCUS) News, Articles, Events & Latest Updates - Stocktwits
RCUS Looks 129.7% Overvalued on GF Value™ - GuruFocus
RCUS SWOT Analysis: Financial Struggles and Competitive Pressures Revealed in 10-Q Filing - GuruFocus
Arcus Biosciences (NYSE:RCUS) Releases Earnings Results, Beats Expectations By $0.17 EPS - MarketBeat
Arcus Biosciences, Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:RCUS) 2026-08-05 - Seeking Alpha
Arcus Q2 2026 slides: casdatifan leads oncology, immunology push - Investing.com
Earnings call transcript: Arcus Biosciences tops Q2 2026 estimates, shares rise - Investing.com
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
RCUS: Casdatifan advances as a potential RCC backbone therapy, supported by robust cash and key data ahead - TradingView
Arcus Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q2 Revenue $41.0M - marketscreener.com
Arcus Biosciences Q2 revenue falls sharply on lower license income - TradingView
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Arcus Biosciences 2Q 2026: Revenue $41M, EPS ($0.72) — 10-Q Summary - TradingView
RCUS: Advanced casdatifan in ccRCC, secured new partnerships, and maintained strong cash runway - TradingView
Arcus Biosciences reports Q2 2026 results: $41M revenue, $775M cash, $91M net loss - TradingView
Arcus Biosciences (NYSE: RCUS) posts Q2 loss, ends Gilead options - Stock Titan
Arcus Biosciences, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Arcus Biosciences earnings in focus as kidney cancer drug advances By Investing.com - Investing.com Nigeria
Arcus Biosciences earnings in focus as kidney cancer drug advances - Investing.com
Dimensional Fund Advisors LP Has $30.80 Million Stake in Arcus Biosciences, Inc. $RCUS - MarketBeat
Earnings To Watch: Arcus Biosciences Inc (RCUS) Q2 2026 -- GF Va - GuruFocus
Arcus Biosciences Inc expected to post a loss of 90 cents a shareEarnings Preview - TradingView
Arcus Biosciences, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 32% Upside - TradingView
BofA Securities Adjusts Arcus Biosciences Price Target to $29 From $25 - Moomoo
Arcus Biosciences (RCUS) Expands Kidney Cancer Collaboration, Is The Stock Still Undervalued? - Sahm
Price-Driven Insight from (RCUS) for Rule-Based Strategy - Stock Traders Daily
How Investors May Respond To Arcus Biosciences (RCUS) Expanding ARC-20 With New Kidney Cancer Combo - Sahm
Arcus Biosciences, Inc. (RCUS) Stock Analysis: Unveiling Near-Term Growth Potential with a 30% Upside - DirectorsTalk Interviews
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):